The invention relates to a compound of formula (II)(see formula II)wherein:each of R1, R2, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15 R16, andR17 isindependently selected from the group consisting of deuterium or hydrogen； andR3 isindependently selected from the group consisting of CD3 or CH3, wherein whenR3 isCH3 then at least one of the groups R1, R2, R4, R5, R6, R7, R8 R9, R10, R11,R12, R13, R14,R15 R16, R17 is deuterium； and R18 is hydrogen. The invention relates to amedicamentfor treating a condition that causes pain, on the basis of said compound. Thetechnicalresult is obtaining new MMP (metalloprotease enzyme) inhibitive compounds,whichexhibit the increased activity, the metabolic stability and or the reducedtoxicity relativeto the currently known MMP inhibitors for the treatment of pain and otherdiseases suchas cancer.
